Atara Bio's PINTA 745 Improves Insulin Sensitivity and Alters Fat Metabolism in Mice Fed With a High Fat Diet

Atara Biotherapeutics, Inc. ATRA, a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today announced the publication of preclinical data that provide insight into the pharmacology of its clinical stage anti-myostatin peptibody, PINTA 745. In the International Journal of Obesity, investigators from Baylor College of Medicine utilized a high fat diet (HFD)-fed mouse model of obesity and type II diabetes to evaluate the effects of myostatin inhibition using PINTA 745. The paper is available at the following web location: http://www.nature.com/ijo/journal/vaop/naam/index.html#05102015 "The data published today further clarify the molecular mechanisms of PINTA 745's pharmacology. The ongoing phase 2 clinical trial with PINTA 745 includes collection of preliminary data on insulin sensitivity, inflammation, and body composition in patients with End-Stage Renal Disease," said Christopher Haqq, MD, PhD, Chief Medical Officer of Atara Bio. "We intend to further explore the role of myostatin inhibition in glucose and fat metabolism."
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!